FinTech founders operate in an environment where innovation, capital, and credibility are tightly linked. Rapid product development, cross‑border operating models and investor scrutiny mean that tax is no longer a back‑office concern but a core part of governance, cash‑flow planning and value creation.
Against this backdrop, Advance Assurance for R&D, corporation tax discipline, and transfer pricing risk management should be viewed as key elements of your tax strategy, allowing you to build early certainty in a business whose value is often driven by intellectual property and future growth.
For many FinTechs, R&D activity is central to the business model and the UK’s R&D tax relief regimes can provide a meaningful source of funding, whether through cash credits or reduced tax liabilities.
At the same time, HMRC scrutiny of R&D claims has increased, and enquiries are increasingly broad in scope, extending beyond R&D into wider tax positions. In parallel, investors are paying closer attention to tax risk during funding rounds and exits.
Questions around loss utilisation, IP ownership, transfer pricing and governance can all affect valuation. The common theme is certainty: businesses that can demonstrate a well‑thought‑through, defensible tax position tend to move more smoothly through due diligence.
This is where Advance Assurance sits – not as a standalone R&D tool, but as part of a wider, proactive approach to tax risk management.
R&D Advance Assurance in context
Advance Assurance is a voluntary HMRC process that allows eligible companies to engage with HMRC before submitting their first R&D tax claims. Where granted, HMRC confirms that it will not normally enquire into the first three R&D claims, provided those claims remain consistent with the information agreed upfront.
More generally, the R&D regime now sits within a more formalised compliance framework. Two features are particularly relevant for FinTechs:
- Pre‑notification: first‑time claimants (or those who have gaps in claiming) must notify HMRC of their intention to claim within six months of the accounting period end. Missing this deadline will invalidate an otherwise legitimate claim.
- Additional Information Form (AIF): all R&D claims must now be supported by a detailed digital submission covering projects, costs and technical justification, before the Corporation Tax return is processed.
Together, these changes mean R&D is no longer something that can be dealt with retrospectively. Advance Assurance aligns naturally with this shift, allowing businesses to build documentation, governance and internal processes that are fit for purpose from the outset.
R&D and Transfer Pricing: An increasingly linked risk
As FinTech groups internationalise, transfer pricing considerations often come into sharper focus – and R&D is frequently the trigger. In recent years, HMRC enquiries into R&D claims have increasingly led to follow‑on questions about transfer pricing. This reflects the reality that R&D activity is closely linked to the creation of valuable intangibles, which in turn underpin how profits are allocated across jurisdictions.
Viewed through that lens, Advance Assurance forms part of a broader, proactive approach to managing cross‑border tax risk. Conceptually, it shares similarities with an Advance Pricing Agreement (APA) in transfer pricing: both seek early engagement with tax authorities to reduce uncertainty.
The scope and suitability are different, with APAs typically being reserved for large or complex intercompany arrangements, but the underlying objective is comparable.
For owner‑managed FinTech start‑ups, a formal APA is rarely appropriate, particularly where UK SME exemptions from transfer pricing rules apply.
However, that exemption often does not extend to overseas jurisdictions. Managing transfer pricing risk outside the UK is therefore critical, especially to ensure that unresolved issues do not surface as negotiation points during due diligence or exit.
For investor‑backed or private‑equity‑controlled FinTech groups, the picture can change. Where IP development is shared across borders and transactions are large or technically complex, more formal transfer pricing certainty (potentially including an APA) may become relevant.
In these cases, Advance Assurance on R&D can sit alongside a more developed transfer pricing framework, reinforcing consistency across the group.
Corporate Tax Discipline: The Foundation Beneath the Incentives
While Advance Assurance can de‑risk R&D claims, it does not exist in isolation. Its effectiveness is underpinned by good corporate tax hygiene.
Strong foundations include:
- clear financial records with appropriate allocation of R&D and non‑R&D costs,
- alignment between management accounts and statutory filings, and
- contemporaneous documentation supporting key tax positions, such as IP ownership and revenue recognition.
Early discipline in these areas reduces the risk of HMRC challenge and makes life easier when investors scrutinise the business.
Loss utilisation is another critical consideration. Many FinTechs are loss‑making in their early years, and decisions around whether to surrender losses for R&D cash credits or carry them forward for future profits can materially affect cash flow and valuation. These decisions should be modelled in the context of growth plans, expected profitability and future tax restrictions.
As businesses scale, tax timing also becomes more important. Corporation tax payment regimes, interaction with R&D credits and overall cash‑flow forecasting all need to be understood to avoid unpleasant surprises as profitability emerges.
Preparing for Investment and Exit
From an investor’s perspective, R&D Advance Assurance is a positive signal as it suggests early engagement with HMRC and reduced risk around a material tax position. But it is only one piece of the puzzle.
Investors increasingly look for evidence that a business has:
- thought holistically about its tax profile,
- addressed transfer pricing and cross‑border risks, and
- maintained consistent, defensible positions over time.
Periodic internal “tax health checks”, carried out well ahead of funding rounds or exits, can help identify and resolve issues before they affect valuation.
A Cohesive Approach to Tax Certainty
Advance Assurance should be seen as part of a joined‑up tax strategy that links R&D incentives, corporate tax planning and transfer pricing risk management for FinTech businesses. Used in this way, it supports not just compliance, but credibility: with HMRC, with investors and with future buyers.
For FinTech leaders navigating rapid growth and increasing scrutiny, that cohesion can be just as valuable as the relief itself.
About the Authors
To discuss a claim for R&D tax relief, now or in the future, please contact Kanika Mishra-Pathak at kanika.mishrapathak@mha.co.uk
https://www.mha.co.uk/about-us/meet-the-team/kanika-mishra-pathak
You can also read more about R&D tax relief by clicking here:
https://www.mha.co.uk/services/tax/research-development
To discuss any other matters regarding tax and transfer pricing in a completely no-obligation way, please contact the following members of our Fintech team:
Peter Carville, Tax Partner – Banks, peter.carville@mha.co.uk
https://www.mha.co.uk/about-us/meet-the-team/peter-carville
Alison Conley, Tax Partner – Investment Funds, alison.conley@mha.co.uk
https://www.mha.co.uk/about-us/meet-the-team/alison-conley
Chris Liu, Transfer Pricing Partner, chris.lie@mha.co.uk
https://www.mha.co.uk/about-us/meet-the-team/chris-liu
Mathias Martini, Senior Manager – Transfer Pricing, mathias.martini@mha.co.uk
Richard Thomas, Director – Corporate Tax, Richard.thomas@mha.co.uk
https://www.mha.co.uk/about-us/meet-the-team/richard-thomas
About MHA
MHA is the UK member firm of Baker Tilly, a global network of accounting and consulting firms providing expert advice across tax planning, assurance, corporate finance and audit. We work with scaling-up Fintechs and established national and global financial services businesses, providing the same level of care and attention to all clients.